Study Evaluating the Pharmacokinetics of Tigecycline in Human Bone

• Status: Completed
• Trial end date: 2008-10-01
• Target enrollment: 0
• Participant gender: All

Summary

Study to examine the concentration of the study drug, tigecycline, in human bone samples following the administration of multiple doses.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer
• Treatments: Minocycline; Tigecycline

Criteria

Inclusion:

• Men and nonlactating and nonpregnant women greater than or equal to 18 years of age.

• Healthy as determined by the investigator on the basis of medical history, physical examination, vital signs, and 12-lead electrocardiogram (ECG).

• Have a high probability for compliance with and completion of the study.

Exclusion:

• Subjects with chronic osteomyelitis.

• Subjects who have known or suspected hypersensitivity to tigecycline or other tetracyclines.

• Involvement in other investigational studies of any type within 30 days before test article administration.